Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study

A legfontosabb adatok

Ki végzi
Tang-Du Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
90 fő, tervezett
Kezdés
2025. febr. 21.
Várható befejezés
2027. márc. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes
  • Umbilical cord mesenchymal stem cell-derived exosomes
  • platelet-rich plasma
A regiszteradat frissítve
2025. március 26.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for women with a thin womb lining after surgery for scar tissue inside the womb, who plan to keep trying IVF or embryo transfer.

Életkor
20 to 40 years
Nem
Women only
A betegség stádiuma
Thin womb lining: under 7 mm in at least one embryo transfer cycle with standard hormone treatment. Ovaries must work normally (AFC ≥ 7, AMH > 1.1 ng/mL).
Korábbi kezelés
Must have had surgery to remove scar tissue in the womb (TCRA), then PRP treatment. Must have had at least one embryo transfer cycle.
Biomarker vagy leletérték
AFC ≥ 7 and AMH > 1.1 ng/mL

A részvétel fő kizáró okai

  • Severe body-wide disease, or cannot have surgery or anesthesia
  • Infection of the reproductive organs, genital tuberculosis, pelvic inflammation, or cancer of the reproductive organs
  • High risk of hormone-dependent tumors such as breast cancer or ovarian tumors
  • Untreated fibroids inside the womb, fibroids ≥5 cm (2 in), adenomyosis, womb shape problems, or polyps
  • Fluid-filled tubes ≥3 cm (1,2 in), ovarian chocolate cysts ≥4 cm (1,6 in), or genetic abnormalities

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Females aged 20-40 years (inclusive of boundary values)
  • Normal ovarian reserve function (criteria: AFC ≥ 7, AMH > 1.1 ng/mL)
  • History of transcervical resection of adhesions (TCRA)
  • Received PRP treatment after TCRA
  • At least one embryo transfer (ET) cycle in which they underwent standard ovarian stimulation (fresh cycle) or standard hormone replacement therapy (FET cycle), with an endometrial thickness of <7 mm
  • Planned to continue IVF/ICSI/FET-assisted conception
  • Able to accept and adhere to treatment and follow-up and willing to sign an informed consent form

Ki nem vehet részt

  • Patients who participated in other clinical trials within 3 months before surgery or during the study period
  • Patients with severe systemic diseases, surgical contraindications, or cycle contraindications
  • Patients with reproductive tract infections, genital tuberculosis, pelvic inflammatory disease, or malignant tumors of reproductive organs
  • Patients with systemic diseases that cause uterine bleeding
  • Patients allergic to any drugs, materials, or components used in this study
  • Patients at high risk for hormone-dependent tumors such as breast cancer or ovarian tumors
  • Patients with untreated submucosal fibroids of any size (FIGO 0/I/II), uterine fibroids ≥5 cm (FIGO III, IV, V, VI, VII), adenomyosis, unicornuate uterus, bicornuate uterus, or endometrial polyps
  • Patients with hydrosalpinx ≥3 cm or hydrosalpinx of any size with significant vaginal discharge
  • Patients with ovarian endometriotic cysts (chocolate cysts) ≥4 cm
  • Patients unable to tolerate anesthesia
  • Patients with genetic abnormalities
  • Other patients deemed unsuitable for participation in this study by the investigator

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 20 és 40 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to evaluate if engineered mechanically umbilical cord-derived stem cell exosomes, or conventional umbilical cord -derived stem cell exosomes, can improve endometrial thickness in women with thin endometrium.

A teljes eredeti leírásKevesebb

The main questions it aims to answer are:

Can exosomes delivered via subendometrial injection improve endometrial thickness or clinical pregnancy rates compared to PRP (platelet-rich plasma)? Are there significant differences in endometrial thickness between the two treatment groups? Researchers will compare the intervention groups, which one group receives mechanical exosomes and the other receives conventional esosomes via subendometrial injection, to the control group, which receives PRP via the same methods, to see if exosomes provide superior therapeutic effects.

Participants will:

Receive either mechanical exosomesor or conventional esosomes or PRP through subendometrial injection.

Be monitored for changes in endometrial parameters.

A vizsgálat 3 csoportja

  • Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosome Group (ME-UCMSC-Exo)A vizsgált kezelés

    Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) containing approximately 5×10¹⁰ particles/mL during the proliferative phase (Day 3-7 of the menstrual cycle). The exosomes are obtained from mechanically preconditioned UC-MSC cultures, which are subjected to biomechanical stress during expansion to enhance regenerative properties. The study aims to evaluate the efficacy of ME-UCMSC-Exo in improving endometrial thickness and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions.

    Kezelés: Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes

  • Conventional Umbilical Cord Mesenchymal Stem Cell-Derived Exosome Group (UCMSC-Exo)A vizsgált kezelés

    Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL conventional umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) containing approximately 5×10¹⁰ particles/mL during the proliferative phase (Day 3-7 of the menstrual cycle). Unlike the ME-UCMSC-Exo group, these exosomes are obtained from standard UC-MSC cultures without mechanical stress preconditioning. This group serves as a comparator to determine whether mechanical preconditioning enhances exosome efficacy in endometrial regeneration and pregnancy outcomes.

    Kezelés: Umbilical cord mesenchymal stem cell-derived exosomes

  • Platelet-Rich Plasma (PRP) Control GroupMár használt kezelés, összehasonlításként

    Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL autologous PRP following standard PRP preparation protocols during the proliferative phase (Day 3-7 of the menstrual cycle). PRP contains growth factors such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β), which have been shown to improve endometrial receptivity and pregnancy outcomes. This group serves as a positive control for assessing the efficacy of exosome-based therapies.

    Kezelés: platelet-rich plasma

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the Therapeutic Effects of Mechanically Engineered Umbilical Cord-Derived Stem Cell Exosomes on Endometrial Injury: A Prospective, Non-Randomized, Parallel-Controlled Clinical Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Illeszkedési kérdések
Forrás: NCT06896747: ki vehet részt
A regiszteradat frissítve
2025. március 26.